PURPOSE: We sought to determine the role of sex hormone-binding globulin in @entity1 with @entity4810 . MATERIALS AND METHODS: We retrospectively reviewed the records of 168 males seen at a fertility clinic from 2012 to 2014, to investigate the accuracy of total @entity251 in the biochemical diagnosis of @entity6126 using calculated bioavailable @entity251 as the reference value. We used multivariable analysis to assess sex hormone-binding globulin as an independent predictor of @entity249 . RESULTS: Computations using calculated bioavailable @entity251 as a standard in the measurement of definitive biochemical @entity6126 (less than 156 ng/dl) revealed 81% sensitivity, 83% specificity, 81% positive predictive value and 82% negative predictive value for diagnosing @entity6126 with total @entity251 alone. Of the 90 @entity1 with total @entity251 greater than 300 ng/dl, 20% had low bioavailable @entity251 less than 156 ng/dl, 52% had borderline low bioavailable @entity251 less than 210 ng/dl and only 48% could be considered biochemically eugonadal according to calculated bioavailable @entity251 . Of the 80 @entity1 with total @entity251 less than 300 ng/dl, 19% had free @entity251 levels greater than 6.5 ng/dl and, thus, could be considered to be eugonadal. By a magnitude similar to that of follicle-stimulating hormone, sex hormone-binding globulin independently predicted decreased sperm concentration (p = 0.0027) and motility (p = 0.0447). After excluding @entity1 with @entity3893 , only sex hormone-binding globulin levels differed significantly in classically hypogonadal @entity1 (group 1-total @entity251 less than 300 ng/dl) and those missed but hypogonadal (group 2-calculated bioavailable @entity251 less than 210 ng/dl) (p = 0.0001). At a more stringent cutoff of calculated bioavailable @entity251 less than 156 ng/dl, sperm motility was significantly different for groups 1 and 2 (p = 0.014). CONCLUSIONS: Adding sex hormone-binding globulin to total @entity251 serum testing facilitates more accurate diagnosis with free @entity251 and calculated bioavailable @entity251 , and clinical implications of decreased semen parameters to a magnitude similar to that of follicle-stimulating hormone. This warrants further study of the role of sex hormone-binding globulin in @entity4810 .

The Utility of Sex Hormone Binding Globulin in XXXX and Infertile Males.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity4810 :: ('MESH:D007248', 'Disease') :: ['male infertility'] @entity6126 :: ('MESH:D007006', 'Disease') :: ['hypogonadism'] @entity3893 :: ('MESH:D053713', 'Disease') :: ['azoospermia']
@entity6126 :: (MESH:D007006,Disease) :: ['Hypogonadism']
